A recent review explored how common diabetes medications like metformin, SGLT2 inhibitors, and GLP-1 receptor agonists might influence cancer growth. While diabetes is linked to higher cancer risk, researchers are investigating if these drugs affect cell multiplication, immune response, and inflammation. The study suggests potential new treatment strategies but emphasizes that much remains unknown about the complex biological pathways involved. Further research is needed to clarify the precise impact of these medications on cancer prevention and care.